Last reviewed · How we verify
Bilastine 20 mg — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Bilastine 20 mg (Bilastine 20 mg) — Association Asthma, Bulgaria.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bilastine 20 mg TARGET | Bilastine 20 mg | Association Asthma, Bulgaria | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bilastine 20 mg CI watch — RSS
- Bilastine 20 mg CI watch — Atom
- Bilastine 20 mg CI watch — JSON
- Bilastine 20 mg alone — RSS
Cite this brief
Drug Landscape (2026). Bilastine 20 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/bilastine-20-mg. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab